

NOV - 7 1997

October 13, 1997

Re: 510(k) SAFETY and EFFECTIVENESS SUMMARY page 1 of 2

Pursuant to Section 510(k) of the Federal Food, Drug and Cosmetic Act, Safety and Effectiveness information is enclosed for the following device:

Device Name: Anti-Stick Syringe with Integral Hypodermic Needle
Trade Name: VanishPoint™ Syringe
Common Name: Safety Syringe
Classification Name: Piston Syringe/Anti-Stick Syringe

Device Class: Class II Medical Device
Classification Panel: Panel 80 (General Hospital and Personal Use)
Procode: MEG - Anti-Stick Syringe

Performance Standard: None established for hypodermic syringes.

Safety and Effectiveness: No new issues of safety or effectiveness when prepared.
The 1cc VanishPoint® Syringe is a smaller version and is substantially equivalent to the original 3cc VanishPoint® which was introduced into the market in December 1995, and the 5cc and 10cc VanishPoint® Syringes which were introduced May 1997.

Facility Address: Retractable Technologies, Inc.
511 Lobo Lane, P.O. Box 9
Little Elm, TX 75068-0009

Establishment Registration Number: 1647137

Indications for Use: The function of the VanishPoint® Syringe is to provide a safe and reliable method of injecting medication into a patient or withdrawing blood from a patient. The VanishPoint® Syringe works like a conventional hypodermic syringe except for its ability to retract the contaminated needle inside of the syringe immediately after patient injection. Needle retraction is activated by the syringe user. Because the contaminated needle is automatically withdrawn into the syringe barrel, the syringe user is protected from accidental needle sticks. These accidental needlesticks would occur between removing the needle from the patient and disposing of the syringe in a sharps disposable container.

510(k) SAFETY and EFFECTIVENESS SUMMARY page 2 of 2

Substantial Equivalence The 1 cc VanishPoint® is a smaller version of the original
3 cc VanishPoint® originally called a Pop n' Lok Syringe.

Contact Information:

Name: Terance Grisso
 Director, Regulatory Affairs and Quality

Address: Retractable Technologies, Inc.
 511 Lobo Lane, P.O. Box 9
 Little Elm, TX 75068-0009

Telephone: (972) 294-1010

Facsimile: (972) 294-4400



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Terance Grisso
Director, Regulatory Affairs and Quality
Retractable Technologies, Incorporated
511 Lobo Lane
Little Elm, Texas 75068

NOV - 7 1997

Re: K973301
Trade Name: VanishPoint® Syringe
Regulatory Class: II
Product Code: MEG
Dated: August 28, 1997
Received: September 2, 1997

Dear Mr. Grisso:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531

through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Timothy A. Ulatowski
Director
Division of Dental, Infection Control
and General Hospital Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K973301

INDICATIONS FOR USE

510 (k) Number (if known): _____

Device Name: VanishPoint® Syringe

Indications for use:

The function of the VanishPoint® Syringe is to provide a safe and reliable method of injecting medication into a patient or withdrawing blood from a patient. The VanishPoint® Syringe works like a conventional hypodermic syringe except for its ability to retract the contaminated needle inside of the syringe immediately after patient injection. Needle retraction is activated by the syringe user. Because the contaminated needle is automatically withdrawn into the syringe barrel, the syringe user is protected from accidental needlesticks. These accidental needlesticks would occur between removing the needle from the patient and disposing of the syringe in a sharps disposable container.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Patricia Cuervo
(Division Sign-Off)
Division of Dental, Infection Control,
and General Hospital Devices
510(k) Number K973301

Prescription Use OR

Over-The-Counter Use

for allergy syringes

for insulin syringes

(Optional Format 1-2-96)